Treatment of African histoplasmosis with ketoconazole

Abstract

The current medical treatment of African histoplasmosis (histoplasmosis duboisii) with amphotericin B has a number of disadvantages ranging from the high incidence of side effects to problems of drug administration. The patient described in this report received the new oral imidazole, ketoconazole, for localized African histoplasmosis which had not responded to amphotericin B, and the disease went into remission. The potential advantages of using ketoconazole in this infection are discussed.